cogt: the income statement

MyFinsight

Cogent Biosciences, Inc. (COGT)

For the quarter ending 2025-06-30, COGT made $2,373K in revenue. -$73,680K in net income. Net profit margin of -3104.93%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Net unrealized losses on marketable securities	-151
Total other comprehensive loss	-151
Research and development	62,203
General and administrative	13,379
Total operating expenses	75,582
Loss from operations	-75,582
Other income (expense), net	-6
Interest income	2,373
Interest expense	314
Total other income, net	2,053
Net loss	-73,529
Comprehensive loss	-73,680

Net loss per common share, basic	-0.53
Net loss per common share, diluted	-0.53
Weighted average common shares outstanding, basic	114,466,080
Weighted average common shares outstanding, diluted	114,466,080

Unit: Thousand (K) dollars (except for numbers of shares and EPS)